
A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. Section 329-14, Hawaii Revised Statutes, is
2 amended by amending subsection (g) to read as follows:

3 "(g) Any of the following cannabinoids, their salts,
4 isomers, and salts of isomers, unless specifically excepted,
5 whenever the existence of these salts, isomers, and salts of
6 isomers is possible within the specific chemical designation:

7 (1) Tetrahydrocannabinols; meaning tetrahydrocannabinols
8 naturally contained in a plant of the genus Cannabis
9 (cannabis plant), as well as synthetic equivalents of
10 the substances contained in the plant, or in the
11 resinous extractives of Cannabis, sp. or synthetic
12 substances, derivatives, and their isomers with
13 similar chemical structure and pharmacological
14 activity to those substances contained in the plant,
15 such as the following: Delta 1 cis or trans
16 tetrahydrocannabinol, and their optical isomers; Delta
17 6 cis or trans tetrahydrocannabinol, and their optical



1 isomers; and Delta 3,4 cis or trans-
2 tetrahydrocannabinol, and its optical isomers (since
3 nomenclature of these substances is not
4 internationally standardized, compounds of these
5 structures, regardless of numerical designation of
6 atomic positions, are covered); except a drug product
7 in finished dosage formulation that has been approved
8 by the United States Food and Drug Administration that
9 contains cannabidiol (2-[1R-3-methyl-6R-(1-
10 methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-
11 benzenediol) derived from cannabis and no more than
12 0.1 per cent (w/w) residual tetrahydrocannabinols;
13 (2) Naphthoylindoles; meaning any compound containing a 3-
14 (1-naphthoyl)indole structure with substitution at the
15 nitrogen atom of the indole ring by a alkyl,
16 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
17 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
18 morpholinyl)ethyl group, whether or not further
19 substituted in the indole ring to any extent and
20 whether or not substituted in the naphthyl ring to any
21 extent;



- 1 (3) Naphthylmethylindoles; meaning any compound containing
2 a 1H-indol-3-yl-(1-naphthyl) methane structure with
3 substitution at the nitrogen atom of the indole ring
4 by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
5 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
6 2-(4-morpholinyl) ethyl group whether or not further
7 substituted in the indole ring to any extent and
8 whether or not substituted in the naphthyl ring to any
9 extent;
- 10 (4) Naphthoylpyrroles; meaning any compound containing a
11 3-(1-naphthoyl)pyrrole structure with substitution at
12 the nitrogen atom of the pyrrole ring by a alkyl,
13 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
14 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)
15 ethyl group whether or not further substituted in the
16 pyrrole ring to any extent, whether or not substituted
17 in the naphthyl ring to any extent;
- 18 (5) Naphthylmethylindenes; meaning any compound containing
19 a naphthylideneindene structure with substitution at
20 the 3-position of the indene ring by a alkyl,
21 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,



1 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
2 ethyl group whether or not further substituted in the
3 indene ring to any extent, whether or not substituted
4 in the naphthyl ring to any extent;

5 (6) Phenylacetylindoles; meaning any compound containing a
6 3-phenylacetylindole structure with substitution at
7 the nitrogen atom of the indole ring by a alkyl,
8 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
9 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
10 ethyl group whether or not further substituted in the
11 indole ring to any extent, whether or not substituted
12 in the phenyl ring to any extent;

13 (7) Cyclohexylphenols; meaning any compound containing a
14 2-(3-hydroxycyclohexyl) phenol structure with
15 substitution at the 5-position of the phenolic ring by
16 a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
17 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
18 2-(4-morpholinyl) ethyl group whether or not
19 substituted in the cyclohexyl ring to any extent;

20 (8) Benzoylindoles; meaning any compound containing a 3-
21 (benzoyl) indole structure with substitution at the



1 nitrogen atom of the indole ring by a alkyl,
2 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
3 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-
4 morpholinyl) ethyl group whether or not further
5 substituted in the indole ring to any extent and
6 whether or not substituted in the phenyl ring to any
7 extent;

8 (9) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
9 pyrrolo[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-
10 naphthalenylmethanone (another trade name is WIN
11 55,212-2);

12 (10) (6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-
13 methyloctan-2-yl)-6a,7,10,10a-
14 tetrahydrobenzo[c]chromen-1-ol (Other trade names are:
15 HU-210/HU-211);

16 (11) Tetramethylcyclopropanoylindoles; meaning any compound
17 containing a 3-tetramethylcyclopropanoylindole
18 structure with substitution at the nitrogen atom of
19 the indole ring by an alkyl, haloalkyl, cyanoalkyl,
20 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
21 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,



- 1 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
2 morpholinyl)methyl, or tetrahydropyranylmethyl group,
3 whether or not further substituted in the indole ring
4 to any extent and whether or not substituted in the
5 tetramethylcyclopropyl ring to any extent;
- 6 (12) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,
7 its optical, positional, and geometric isomers, salts,
8 and salts of isomers (Other names: APINACA, AKB48);
- 9 (13) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its
10 optical, positional, and geometric isomers, salts, and
11 salts of isomers (Other names: PB-22; QUPIC);
- 12 (14) Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-
13 carboxylate, its optical, positional, and geometric
14 isomers, salts, and salts of isomers (Other names: 5-
15 fluoro-PB-22; 5F-PB-22);
- 16 (15) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
17 fluorobenzyl)-1H-indazole-3-carboxamide, its optical,
18 positional, and geometric isomers, salts, and salts of
19 isomers (Other names: AB-FUBINACA);
- 20 (16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
21 indazole-3-carboxamide, its optical, positional, and



- 1 geometric isomers, salts, and salts of isomers (Other
2 names: ADB-PINACA);
- 3 (17) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
4 (cyclohexylmethyl)-1H-indazole-3-carboxamide, its
5 optical, positional, and geometric isomers, salts, and
6 salts of isomers (Other names: AB-CHMINACA);
- 7 (18) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
8 indazole-3-carboxamide, and geometric isomers, salts,
9 and salts of isomers (Other names: AB-PINACA);
- 10 (19) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-
11 yl)methanone, and geometric isomers, salts, and salts
12 of isomers (Other names: THJ-2201);
- 13 (20) Methyl (1-(4-fluorobenzyl)-1 H-indazole-3-carbonyl)-L-
14 valinate, and geometric isomers, salts, and salts of
15 isomers (Other names: FUB-AMB);
- 16 (21) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
17 carboxamido)-3-methylbutanoate, and geometric isomers,
18 salts, and salts of isomers (Other names: 5-fluoro-
19 AMB, 5-fluoro-AMP);
- 20 (22) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-
21 indazole-3-carboxamide, and geometric isomers, salts,



- 1 and salts of isomers (Other names: AKB48 N-(5-
2 fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl
3 analog, 5F-APINACA);
- 4 (23) N-adamantyl-1-fluoropentylindole-3-Carboxamide, and
5 geometric isomers, salts, and salts of isomers (Other
6 names: STS-135, 5F-APICA; 5-fluoro-APICA);
- 7 (24) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
8 carboxylate, and geometric isomers, salts, and salts
9 of isomers (Other names: NM2201);
- 10 (25) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
11 (cyclohexylmethyl)-1H-indazole-3-carboxamide, and
12 geometric isomers, salts, and salts of isomers (Other
13 names: MAB-CHMINACA and ADB-CHMINACA);
- 14 (26) Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-
15 carboxamido]-3,3-dimethylbutanoate (Other names: 5F-
16 ADB, 5-flouro-ADB, and 5F-MDMB-PINACA), its optical,
17 positional, and geometric isomers, salts, and salts of
18 isomers; and
- 19 (27) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-
20 carboxamide (CUMYL-4CN-BINACA), its optical,
21 positional, and geometric isomers, salts, and salts of



1 isomers; also known as SGT-78, 4-CN-CUMYL-BINACA;
2 CUMYL-CB-PINACA; CUMYL-CYBINACA; 4-cyano CUMYL-
3 BUTINACA."

4 SECTION 2. Section 329-22, Hawaii Revised Statutes, is
5 amended to read as follows:

6 "§329-22 Schedule V. (a) The controlled substances
7 listed in this section are included in schedule V.

8 (b) Narcotic drugs containing nonnarcotic active medicinal
9 ingredients. Any compound, mixture, or preparation containing
10 limited quantities of any of the following narcotic drugs, which
11 also contains one or more nonnarcotic active medicinal ingredients
12 in sufficient proportion to confer upon the compound, mixture, or
13 preparation, valuable medicinal qualities other than those
14 possessed by the narcotic drug alone:

15 (1) Not more than 200 milligrams of codeine, or any of its
16 salts, per 100 milliliters or per 100 grams;

17 (2) Not more than 100 milligrams of dihydrocodeine, or any
18 of its salts, per 100 milliliters or per 100 grams;

19 (3) Not more than 100 milligrams of ethylmorphine, or any of
20 its salts, per 100 milliliters or per 100 grams;



1 (4) Not more than 2.5 milligrams of diphenoxylate and not
2 less than 25 micrograms of atropine sulfate per dosage
3 unit;

4 (5) Not more than 100 milligrams of opium per 100
5 milliliters or per 100 grams; and

6 (6) Not more than 0.5 milligram of difenoxin and not less
7 than 25 micrograms of atropine sulfate per dosage unit.

8 (c) Stimulants. Unless specifically exempted or excluded
9 or unless listed in another schedule, any material, compound,
10 mixture, or preparation that contains any quantity of the
11 following substances having a stimulant effect on the central
12 nervous system, including its salts, isomers, and salts of
13 isomers.

14 (d) Depressants. Unless specifically exempted or excluded
15 or unless listed in another schedule, any material, compound,
16 mixture, or preparation that contains any quantity of the
17 following substances having a depressant effect on the central
18 nervous system, including its salts, isomers, and salts of
19 isomers:

20 (1) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-
21 propionamide], (Vimpat);



- 1 (2) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic
- 2 acid]; and
- 3 (3) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-
- 4 yl]butanamide) (Other names: BRV; UCB-34714; Briviact)
- 5 and its salts.

6 (e) Approved cannabidiol drugs. A drug product in
 7 finished dosage formulation that has been approved by the United
 8 States Food and Drug Administration that contains cannabidiol
 9 (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-
 10 pentyl-1,3-benzenediol) derived from cannabis and no more than
 11 0.1 per cent (w/w) residual tetrahydrocannabinols."

12 SECTION 3. New statutory material is underscored.

13 SECTION 4. This Act shall take effect upon its approval.

14

INTRODUCED BY:

[Handwritten signatures]



H.B. NO. 290

Report Title:

Uniform Controlled Substances Act

Description:

Updates the Uniform Controlled Substances Act to make it consistent with amendments in federal controlled substances law as required under the authority to schedule controlled substances.

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

